Merck & Co., Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MRK research report →
Range $105 – $180
Price Chart
About the company
Merck & Co. , Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health.
- CEO
- Robert Davis
- IPO
- 1978
- Employees
- 74,000
- HQ
- Rahway, NJ, US
AI snapshot
Six angles, distilled from the data.
The stock is in a constructive uptrend, holding well above its 200-day average and trading near the upper end of its 52-week range. That keeps the longer-term regime bullish, though the move is extended enough that shareholders should watch for consolidation rather than chase momentum.
Street sentiment is constructive: the consensus sits at Buy, with a median target of 165 and a consensus target of 159.45, both above the current quote. Recent revisions have leaned higher, with multiple firms lifting targets into the 155-180 range even as ratings mostly stayed unchanged.
Merck has a clean beat streak, going 8-for-8 over the last eight quarters, including a 17.5% EPS beat in the latest report. Next-year EPS estimates point sharply higher to 8.981, so the setup favors execution on pipeline and margin durability more than simple top-line growth.
Recent insider activity skews to net selling, led by two discretionary sales from officers, while most other entries are awards or exempt transactions that are not meaningful trading signals. The pattern does not show broad insider accumulation, so shareholders should watch whether selling remains isolated or becomes more persistent.
Profitability is solid but not elite: gross margin is 75.2% and operating margin is 35.16%, while net margin is 3.64% after a year with EPS growth of -12.0%. Cash generation is strong at $20.584 billion of free cash flow, but leverage remains meaningful with $50.534 billion of debt against $14.565 billion of cash.
Merck screens as a large-cap pharma name with a premium setup versus the sector, supported by strong cash flow and a beta of 0.12. The valuation still looks full at 46.03x earnings, so the market is paying for pipeline confidence and earnings recovery rather than current profitability.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $329.65B
- P/E
- 144.82
- Fwd P/E
- 48.00
- PEG
- -1.67
- P/S
- 5.25
- P/B
- 7.89
- EV/EBITDA
- 33.69
- Div Yield
- 2.37%
- Gross Margin
- 74.67%
- Op Margin
- 13.64%
- Net Margin
- 3.64%
- ROE
- 5.29%
- ROIC
- 4.37%
Latest fiscal year · YoY change
- Revenue
- $64.93B+1.2%
- Gross Profit
- $46.73B-4.6%
- Op Income
- $23.49B
- Net Income
- $18.25B+6.6%
- EPS
- $7.30+8.0%
- OCF Growth
- -23.3%
- FCF Growth
- -31.7%
- 52W High
- $156.92
- 52W Low
- $95.36
- 50D MA
- $145.48
- 200D MA
- $129.15
- Beta
- 0.22
- RSI (14)
- 32
- Avg Volume
- 9.82M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Merck delivered a solid third quarter, raised full-year guidance, and highlighted major late-stage pipeline wins in oncology while reaffirming confidence in growth beyond the Keytruda LOE period.· October 29, 2026
- Q3 revenue was $18.1 billion, up 5% reported and 4% ex-FX; non-GAAP EPS was $2.49, including a $0.12-per-share Ceybrion charge.
- Full-year 2026 guidance was narrowed and raised: revenue to $66.8 billion-$67.3 billion and EPS to $2.77-$2.82, both including a positive FX impact.
- Keytruda family sales rose 6% to $8.6 billion; Gardasil grew 14% to $2.0 billion; WINREVAIR nearly doubled to $694 million; OHTUVAYRE and LIPFENDRA added to the launch momentum.
- Management pointed to multiple pipeline de-risking events, including positive Phase III endometrial cancer data for sac-TMT, positive melanoma vaccine data for entismodigene, and encouraging ophthalmology and immunology readouts.
- Management also flagged known 2027 headwinds from generic competition, Keytruda maturation, and vaccine market dynamics, while saying the company expects to return to growth after a shallow dip around the LOE period.
Total company revenues were $18.1 billion, up 5% reported and 4% excluding foreign exchange. On a non-GAAP basis, gross margin was 81.4%, operating expenses were $7.4 billion, other expense was $420 million, the tax rate was 10.9%, and EPS was $2.49, including a $0.12-per-share charge related to the Ceybrion license agreement. Keytruda family sales increased 6% to $8.6 billion; KEYTRUDA QLEX sales were $830 million. Other product sales mentioned included WELIREG at $370 million, Gardasil at $2.0 billion, CAPVAXIVE at $263 million, WINFLONZIA at $187 million, WINREVAIR at $694 million, and OHTUVAYRE at $184 million. Full-year 2026 guidance was raised to revenue of $66.8 billion-$67.3 billion and EPS of $2.77-$2.82; gross margin is expected to remain around 81%, operating expenses at $42.4 billion-$42.9 billion, other expense at about $1.4 billion, and the tax rate at 32%-33%. Management said third-quarter sales benefited by about $550 million from favorable U.S. purchase timing, which is expected to unwind.
Robert Davis struck an upbeat tone, saying 2026 is showing “substantial progress” and that the company is “executing well on all fronts.” He emphasized that new product launches and clinical milestones are increasingly translating into commercial results and de-risking the long-term opportunity beyond Keytruda LOE. He also said the company is gaining confidence in its ability to deliver long-term value through launches, pipeline expansion, and continued investment.
Caroline Litchfield focused on the quarter’s financial execution and the updated outlook. She said revenue grew 5% reported and 4% ex-FX, gross margin was 81.4%, operating expenses rose 12% to $7.4 billion, and EPS was $2.49 including the Ceybrion charge. She detailed the raised 2026 guide, noted a $550 million Q3 timing benefit split across Keytruda, WINREVAIR, and vaccines, and reiterated capital allocation priorities including the dividend, business development, and about $3 billion of share repurchases this year.
Analysts pressed management on whether 2027 consensus already reflects the company’s “moderate” growth outlook and whether higher R&D spending is pulling forward the earnings trough. Caroline said 2027 is another year of investment, with moderate top-line growth partly offset by more than $2 billion of headwinds from generic competition and LOE, but she also said earnings should eventually resume growth as the pipeline and launches scale. Other notable questions focused on WINREVAIR’s one-time benefit, KEYTRUDA QLEX litigation in Europe, LIPFENDRA uptake and access, and the outlook for sac-TMT, TL1A, and other pipeline assets; management consistently emphasized strong early adoption, active FDA engagement, and a belief that the key programs can support future growth.
The call featured multiple positive clinical and commercial catalysts: strong early launch momentum across new products, a raised 2026 outlook, and several late-stage readouts that management described as practice-changing or landmark. Management said the pipeline is increasingly de-risked and repeatedly expressed confidence that these assets can offset Keytruda’s eventual decline and support growth into the 2030s.
Management was clear that 2027 will bring meaningful headwinds from generic competition, Keytruda maturation, vaccine demand normalization, and policy pressure in Germany. QLEX litigation in Europe remains unresolved, some launches still face access buildout, and several programs still need additional readouts or regulatory filings before their value is fully proven.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.9%
- Shares Outstanding
- 2.47B
- Float Shares
- 2.46B
of shares held by institutions
3,969 13F filers
Buy/sell ratio 1.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for MRK, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Ro KhannaHouse · CA17 | Buy | Oct 2, 26 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Oct 7, 26 | Filing → |
| Michael McCaulHouse · TX10 | Sell | Aug 28, 26 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Sep 4, 26 | Filing → |
| Maria Elvira SalazarHouse · FL27 | Sell | Sep 24, 26 | Filing → |
| Maria Elvira SalazarHouse · FL27 | Buy | Aug 19, 26 | Filing → |
| Maria Elvira SalazarHouse · FL27 | Buy | Aug 19, 26 | Filing → |
| Maria Elvira SalazarHouse · FL27 | Buy | Aug 19, 26 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Aug 7, 26 | Filing → |
| Alan ArmstrongSenate | Sell | Mar 27, 26 | Filing → |
| Keith SelfHouse | Sell | Jan 10, 25 | Filing → |
| Josh GottheimerHouse · NJ05 | Buy | Feb 4, 26 | Filing → |
| Michael T. McCaulHouse · TX10 | Sell | Jan 13, 26 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Jan 29, 26 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 254.32M | ▲ 2.19M |
| Blackrock, Inc. | 227.00M | ▲ 1.17M |
| Vanguard Capital Management LLC | 161.32M | ▲ 335.55K |
| State Street Corp | 121.42M | ▲ 1.01M |
| Wellington Management Group Llp | 86.25M | ▲ 1.93M |
| Vanguard Portfolio Management LLC | 67.74M | ▲ 434.66K |
| Geode Capital Management, LLC | 61.57M | ▲ 821.49K |
| Charles Schwab Investment Management Inc | 54.37M | ▲ 4.60M |
| Sixth Street Partners Management Company, L.P. | 54.37M | ▲ 54.37M |
| Morgan Stanley | 48.64M | ▲ 1.01M |
| Fmr LLC | 46.22M | ▲ 781.70K |
| Jpmorgan Chase & Co | 43.12M | ▼ 771.09K |
Held by 3,082 ETFs
Biggest fund positions in MRK by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 12, 26 | DeLuca Richard R. | other | 58,185 |
| Nov 12, 26 | DeLuca Richard R. | sell | 58,185 |
| Nov 12, 26 | DeLuca Richard R. | other | 58,185 |
| Nov 1, 26 | DIAZ PAUL J | other | 613.073 |
| Nov 1, 26 | DIAZ PAUL J | other | 0 |
| Nov 1, 26 | DIAZ PAUL J | other | 0 |
| May 1, 26 | Maraldo David R. | other | 0 |
| Sep 30, 26 | Seidman Christine E | other | 55.915 |
| Sep 30, 26 | Karsanbhai Surendralal Lanca | other | 111.83 |
| Sep 30, 26 | Coe Mary Ellen | other | 206.455 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our MRK coverage
Recent articles, reports, and earnings notes.

Merck & Company (MRK): KEYTRUDA Growth vs. Patent Risk
Merck is a Buy as KEYTRUDA still drives growth, WINREVAIR is scaling fast, and the pipeline offers a path through the 2028 patent transition. The stock remains a transition story, but new products and late-stage oncology assets support the case.

Merck & Co., Inc. (MRK) rises 5.3% on Q3 earnings
Merck & Co., Inc. (MRK) rises after reporting stronger-than-expected third-quarter results, led by $18.1 billion in sales, $2.04 GAAP EPS, and standout growth from KEYTRUDA and WINREVAIR. Investors also reacted to encouraging oncology data and a constructive full-year outlook, though valuation remains elevated.

Merck & Co. (MRK): Pipeline Growth vs. Keytruda Risk
Merck is a high-quality pharma franchise with strong cash flow, but the stock is balancing new product growth against looming Keytruda exclusivity risk. The shares look fairly valued at current levels, supporting a Hold.
Want a deeper read on MRK?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
1 High-Flying Stock to Buy Hand Over Fist if the Stock Market Crashes
fool.com · Nov 20
Merck Reports Positive Survival Data For Investigational Therapy for Advanced Gastric Cancer
benzinga.com · Nov 20
HALO Faces Legal Setback in Germany Over MRK's Keytruda SC, Stock Down
zacks.com · Nov 20
Merck's drug prolongs survival in advanced stomach, esophageal cancers in trial
reuters.com · Nov 20
Halozyme Stock Slides, European Patent Fight With Merck Spurs Fresh Pressure
benzinga.com · Nov 19
Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know
zacks.com · Nov 19
Merck & Co., Inc. (MRK) Presents at Jefferies London Healthcare Conference Transcript
seekingalpha.com · Nov 19
Merck & Co. Eyes Kidney Cancer Data as Vaccine Research Expands Beyond Melanoma
marketbeat.com · Nov 19
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 14, 2026 · Live quote · Not investment advice